Diagnose and treat mild to moderate alzheimer’s disease

Nurse Practitioner

Volumn 27, Issue 12, 2002, Pages 13-25

  Griffith, Veronica T ^a  

^a Internal Medicine Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; HUMAN; PRACTICE GUIDELINE;

AGED; ALZHEIMER DISEASE; HUMANS; PRACTICE GUIDELINES;

EID: 0036885744     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200212000-00003     Document Type: Article

References (40)

1. Small G, Rabins P, Barry P, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997; 278(16):1363-71.
2. Francis P, Palmer A, Snape M, et al.: The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J Neurol Neurosurg Psychiatry 1999; 66(2):137-47.
3. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88(9):1337-42.
4. Boise L, Camicioli R, Morgan DL, et al.: Diagnosing dementia: Perspectives of primary care physicians. Gerontologist 1999; 39(4):457-64.
5. Knopman D, Donohue J, Gutterman E: Patterns of care in the early stages of Alzheimer’s disease: Impediments to timely diagnosis. J Am Geriatr Soc 2000; 48(3):300-404.
6. Lim A, Tsuang D, Kukull W, et al.: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999; 47(5):564-69.
7. Lopez O, Becker J, Klunk W, et al.: Research evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I. Neurology 2000; 55(12):1854-62.
8. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, D.C.: American Psychiatric Association, 2000.
9. Folstein M, Folstein S, McHugh P: Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975; 12:189-98.
10. Sunderland T, Hill J, Mellow A, et al.: Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc 1989; 37(8):725-29.
11. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141(11):1356-64.
12. McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34(7):939-44.
13. Spiegel R, Brunner C, Ermini-Funfschilling D, et al.: A new behavioral assessment scale for geriatric out- and in-patients: The NOSGER (Nurses’ Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991; 39(4):339-47.
14. Pfeffer R, Kurosaki T, Harrah CJ, et al.: Measurement of functional activities in older adults in the community. J Gerontol 1982; 37(3):323-29.
15. Doody R, Geldmacher D, Gordon B, et al.: Open-label, multicenter, phase III extension study of the safety and efficacy of donepezil in patients with Alzheimer’s disease. Arch Neurol 2001; 58:427-33.
16. Burns A, Rossor M, Hecker J, et al.: The effects of donepezil in Alzheimer’s disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3):237-44.
17. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000; 321(7274):1445-49.
18. Rosler M, Anand R, Cicin-Sain A, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: International randomised controlled trial. Br Med J 1999; 318(7184):633-38.
19. Hill J, Futterman R, Mastey V, et al.: The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface 2002; 15(3):63-70.
20. Small G, Donohue J, Brooks R: An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Therapeutics 1998; 20(4):838-50.
21. Leon J, Cheng C-K, Neumann P: Alzheimer’s disease care: Costs and potential savings. Health Affairs 1998; 17(6):206-16.
22. Galasko D: An integrated approach to the management of Alzheimer’s disease: Assessing cognition, function and behaviour. Eur J Neurol 1998; 5(suppl 4):S9-S17.
23. Zec RF, Landreth ES, Vicari SK, et al.: Alzheimer disease assessment scale: Useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1992; 6(2):89-102.
24. Winblad B, Engedal K, Soininen H, et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57(3):489-95.
25. Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57(4):613-20.
26. Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine U.S.A.-10 Study Group. Neurology. 2000; 54(12):2269-76.
27. Raskind MA, Peskind ER, Wessel T, et al.: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine U.S.A.-1 Study Group. Neurology 2000; 54(12):2261-68.
28. Mohs RC, Doody RS, Morris JC, et al.: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57(3):481-88.
29. Mittelman M, Ferris S, Shulman E, et al.: A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996; 276(21):1725-31.
30. Provenzano G, Duttagupta S, McRae T, et al.: Delays in nursing home placement for patients with Alzheimer’s disease associated with treatment with donepezil may have health care cost-saving implications. Value in Health 2001; 4(2):158.
31. Rice DP, Fillit HM, Max W, et al.: Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: A managed care perspective. Am J Manag Care 2001; 7(8):809-18.
32. Schulz R, O’Brien AT, Bookwala J, et al.: Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995; 35(6):771-91.
33. Hammerlein A, Derendorf H, Lowenthal DT: Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998; 35(1):49-64.
34. Eisai, Inc.: Aricept package insert. Teaneck, N.J.: Eisai Inc., 2001.
35. Novartis: Exelon package insert. East Hanover, N.J.: Novartis, 2001.
36. Janssen Pharmaceutica: Reminyl package insert. Titusville, N.J.: Janssen Pharmaceutica, 2001.
37. Wilkinson D, Hock, C, Icni, J, Bahra R: A multinational, randomized, 12-week comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 2002; 56:441-446.
38. Spencer C, Noble S: Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging 1998; 13(5):391-411.
39. Babic T, Banfic L, Papa J, et al.: Spontaneous rupture of oesophagus (Boerhaave’s syndrome) related to rivastigmine. Age Aging 2000; 29(4):370-71.
40. Galasko D, Edland S, Morris J, et al.: The consortium to establish a registry for Alzheimer’s disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer’s disease followed over 3 years. Neurology 1995; 45:1451-55.